

## Mutations in human *TBX3* alter limb, apocrine, and genital development in ulnar-mammary syndrome

Michael Bamshad, Robert C. Lin, David J. Law, W. Scott Watkins, Patrycja A. Krakowiak, Mary E. Moore, Piergiorgio Franceschini, Roberto Lala, Lewis B. Holmes, Tom C. Gebuhr, Benoit Bruneau, Albert Schinzel, John G. Seidman, Christine E. Seidman & Lynn B. Jorde

*Nature Genet.* **16**, 311–315 (1997).

In sequencing additional *TBX3* cDNA clones, Dr. Chris Campbell brought to our attention a single base insertion at nt 1107 which causes a frameshift in the *TBX3* sequence (GenBank accession number AF002228). Sequencing of PCR-derived genomic templates of *TBX3* confirms this finding. A corrected *TBX3* sequence from the start of exon 6 to the end of the published sequence is shown below. The authors regret this error.

```

1039 GATTTATGTCCCAGCGAGGGTGAGAGCGACGCCGAGGCCGAGACAAAGAGGAGCAC
    AspLeuCysProSerGluGlyGluSerAspAlaGluAlaGluSerLysGluGluHis
    ↓
1096 GGCCCCGAGGCCTGCGACGCGGCCAAGATCTCCACCACCACGTCGGGGAGCCCTGCC
    GlyProGluAlaCysAspAlaAlaLysIleSerThrThrThrSerGluGluProCys
1153 GTGACAAGGGCAGCCCCGCGTCAAGGCTCACCTTTTCGCTGCTGAGCGGCCCGGG
    ArgAspLysGlySerProAlaValLysAlaHisLeuPheAlaAlaGluArgProArg
1210 ACAGCGGGCGGCTGGACAAAGCGTCGCCCGACTCAGCCATAGCCCCGCCACCATCT
    AspSerGlyArgLeuAspLysAlaSerProAspSerArgHisSerProAlaThrIle
1267 CGTCCAGCACTCGCGGCTGGGCGCGGAGGAGCGCAGGAGCCCGGTTCCGCGAGGGCA
    SerSerSerThrArgGlyLeuGlyAlaGluGluArgArgSerProValArgGluGly
1324 CAGCGCCGGCCAAGGTGGAAGAGGCGCGCGCTCCCGGGCAAGGAGGCCTTCGCGC
    ThrAlaProAlaLysValGluGluAlaArgAlaLeuProGlyLysGluAlaPheAla
1381 CGCTCACGGTGCAGACGACGCGG
    ProLeuThrValGlnThrAspAla
    
```

## Growth retardation and tumour inhibition by *BRCA1*

Jeffrey T. Holt, Marilyn E. Thompson, Csilla Szabo, Cheryl Robinson-Benion, Carlos L. Arteaga, Mary-Claire King & Roy A. Jensen

*Nature Genet.* **12**, 298–302 (1996).

The sequence of the *BRCA1* cDNA presumed to be wild-type in these studies actually was that of a splice variant with an altered exon 5 containing nucleotides 22201–22256 (compared with wild-type exon 5 at nucleotides 22201–22278 of GenBank L78833 genomic sequence). This altered splicing results in a protein which initiates at amino acid 72 of wild-type *BRCA1*. The altered sequence is published<sup>1</sup> and the complete splice variant sequence available in GenBank (AF 005068). This error does not affect our main conclusions, as we have subsequently reported that both the prior splice variant and the new full-length *BRCA1* cDNA function as growth inhibitors and tumour suppressors<sup>1</sup>.

```

TGT CCT TT ATG (taagaatgataataccaaaagg) AGC CTA CAA
    splice donor (22 bp spliced from exon 5) splice acceptor
    
```

1. Tait, D.L. et al. A Phase I trial of retroviral *BRCA1*sv gene therapy in ovarian cancer. *Clin. Cancer Res.* **3**, 1959–1978 (1997).

## erratum

### Distribution of olfactory receptor genes in the human genome

Sylvie Rouquier, Sylvie Taviaux, Barbara J. Trask, Véronique Brand-Arpon, Ger van den Engh, Jacques Demaille & Dominique Giorgi

*Nature Genet.* **18**, 243–250 (1998).

Part of the discussion was inadvertently sent to press without the incorporation of the authors' corrections. The correct version is shown below. We regret this error.

Out of 53 sites detected more than once, 28 were labelled with an efficiency >5%, a level considered significant considering the small size of the probes and complex nature of the probe-pool. Several arguments lead to the conclusion that OR genes are very likely to reside at many of the sites detected less efficiently. The specificity and sensitivity of our FISH approach for locating OR sequences are demonstrated by the observation that all previously reported locations of OR genes were detected.